RESULTS:
The study cohort included 6,291,810 patients, mean age 52 years, 57.9% female. The mean MPR and mean PDC for drugs with known abuse potential were both lower than for drugs without known abuse potential. The MPR/PDC ratio (MPR:PDC) ranged from 1.02-1.09. Highest values for the Lorenz-1 curve were seen for acetaminophen with codeine, acetaminophen with oxycodone, oxycodone, and acetaminophen with hydrocodone. The individual MPR and PDC were strongly correlated to each other (r = 0.99; P < 0.001 for both), moderately correlated with the MPR:PDC (r = 0.62 and 0.57, respectively) and moderately inversely correlated with Lorenz 1 (r = -0.83 and -0.86, respectively, P < 0.001 for both). The MPR:PDC was inversely correlated with the Lorenz-1 (r = -0.39; P = 0.02). After rank ordering individual drugs by each measure from highest to lowest value, the MPR:PDC resulted in consistent distributions with the individual MPR (P = 0.0097) and PDC (P = 0.0018), but not the Lorenz-1 (P = 0.0835), nor Lorenz-50 (P = 0.1343). The MPR, PDC, Lorenz-1, and Lorenz-50 were able to discriminate between the drugs with known abuse potential and those without (c-statistic 0.979 to 1), while the MPR:PDC was not (c-statistic 0.592).
CONCLUSIONS: When comparing classes of drugs with a known abuse potential with classes of drugs not prone to such use, using an array of drug utilization measures, significantly different patterns emerge, although the ability of these measures to serve as reliable indicators of the extent of nonmedical prescribing may be limited. There is a need for valid and reliable algorithms to detect the extent of nonmedical use at a population 
What is already known about this subject
• Based on the distribution of drugs ranked highest to lowest by each measure, the MPR, PDC, and MPR/PDC ratio resulted in consistent distributions, but different than that produced by the Lorenz percentiles. The MPR, PDC, and Lorenz percentiles were able to discriminate between abusable and nonabusable drugs, while the MPR/PDC ratio was not.
• When comparing traditional measures of treatment compliance, a novel method of excess drug supply (MPR/PDC ratio), and a measure of skewed utilization pattern, one can observe significantly different patterns, although the ability of these measures to serve as reliable indicators of the extent of nonmedical prescribing may be limited.
the time period of interest and can exceed 1, while the PDC reflects the proportion of days during which any drug supply is available and is capped at 1. Individuals abusing or diverting a given medication might be expected to have a relatively high MPR and/or PDC and thus skew population means for these measures. Martin et al. (2009) suggested that when identification of overuse is important, the PDC measure could be supplemented with traditional MPR calculations but did not suggest how this could be done or interpreted. 6 One such approach could involve taking the ratio of the MPR to the PDC to reflect the "density" of medication availability, which might be more sensitive to irregular prescription fill behavior seen with nonmedical use. Figure 1 shows a hypothetical example of the MPRs, PDCs, and MPR to PDC ratios that result from different refill patterns over a 6-month period.
Another measure that uses prescription claims data to characterize population-level drug utilization is based on the Lorenz curve. The share of total drug volume purchased by the 1% most heavily consuming users of a drug is defined as the Lorenz 1-percentile, while the share of drug volume purchased by the 50% most heavily consuming users of a drug is defined as the Lorenz 50-percentile, and high values for either of these measures suggest a skewed utilization pattern. 7 Measurement of the Lorenz curve has been used to demonstrate heavy use of opioid analgesics and carisprodol. 7, 8 Like MPR and PDC distributions, the Lorenz curve reflects differences in overall drug use within populations but not irregular use by individuals.
The objective of this study was to explore the extent to which claims-based utilization measures can provide information that aids in identifying and quantifying nonmedical drug use. Specifically, we compared values for the measures just described for medications prone to nonmedical use with those for medications that are not. Our hope is that our results will 2007, with a steady increase in opioid abuse during the same time period. 2 The economic burden of nonmedical prescription drug use is also substantial. Using data from the NSDUH, Hansen et al. (2011) estimated that the total cost of nonmedical prescription opioid use in 2006 in the United States was $53.4 billion. 3 Aldridge et al. (2011) estimated that 3.6% of the total costs paid by private insurers for attention deficit hyperactivity disorder (ADHD) medications were for diverted stimulant medications. 4 This resulted in an estimated annual cost of between $83 and $204 million, while White et al. evaluated the direct health care costs paid by private insurers for a population with an opioid abuse diagnosis and found the excess annual cost burden of opioid abuse compared with nonabusers was $14,054 per patient. 5 Drug utilization measures that can reliably quantify the extent of nonmedical use of a given medication or medication class would greatly facilitate efforts to identify, monitor, and constrain nonmedical prescription drug use. Measures making use of prescription claims data would be especially valuable given the ready availability of these data among health care plans and payers. While there is no gold standard for identifying nonmedical drug use, patient prescription refill data may provide suggestive clues. For example, individuals abusing or diverting prescription medications could be expected to fill more prescriptions on average than those using medications as prescribed and may also demonstrate irregular and erratic refill behavior. A number of existing drug utilization measures reflect the total supply of a drug available to a patient over a given time period but are more limited in their ability to detect irregular patterns of use.
The medication possession ratio (MPR) and proportion of days covered (PDC) are commonly used to describe treatment adherence. The MPR reflects total drug supply available during motivate further research aimed at developing more discerning measures of nonmedical use that can be used for public health and quality improvement initiatives.
■■ Methods
To facilitate the ability to distinguish potential patterns of drug abuse/diversion, we chose to evaluate the use of 7 classes of drugs, some with a known abuse potential (benzodiazepines, hypnotics, opioids, stimulants) and some without (calcium channel blockers, thyroid replacement therapy, statins). The opioids and stimulant classes were further divided into weak versus strong, and stimulants into short acting versus long acting. For the opioids, the World Health Organization's classification of analgesics for the management of cancer pain was used, 9 while the stimulants were differentiated by their half-life, similar to what was done in a study by Pohl et al. (2009) . 10 Truven's MarketScan database, a large U.S.-based claims database was used to identify the study cohort. Patients were included if they were aged > 18 years, had 2 or more prescriptions for a benzodiazepine, hypnotic, opioid, calcium channel blocker, thyroid replacement therapy, statin, or stimulant (only solid, oral dosage forms were considered) during the index period between January 1, 2008, and December 31, 2008, and had 1 year of continuous pharmaceutical and medical benefit enrollment after the index period. An index date was defined as the date on which the first prescription for any of the medications of interest was filled by the patient. Although stimulants are often used in children, we chose to limit the patient population to aged > 18 years because, across all of the drug categories of interest, there was overall more drug use in adults versus children, and those aged < 18 years contributed disproportionally across all of the categories. Additionally, this was also the population reported by Aldridge et al. in their research on cost of diversion of ADHD medications. 4 There was not a distinction between current and new users. The specific agents within each class that were included in the analysis were those that were the most frequently prescribed within each class. If an individual was taking medications from more than 1 class, all prescriptions were included in the corresponding calculations for each individual medication taken (Table 1) . Drug utilization was assessed during the first year after an index prescription using traditional adherence measures, a novel method of overlapping days supply (MPR/PDC ratio), and measures of asymmetrical use within a population.
Measures of Drug Utilization
Medication utilization was measured in terms of adherence to individual agents within a drug class, as well as compliance/hypercompliance within a drug class overall. We did not examine compliance/hypercompliance to agents across related medication classes (e.g., weak and strong opioids). The 5 compliance/hypercompliance measures compared are reported in Table 2 .
Statistical Methods
The proportion of individuals falling into each MPR category (MPR ≤ 0.5; MPR = 0.5 to < 0.8; MPR = 0.8 to < 1.0; MPR > 1.0) was calculated for each compound and plotted as histograms. In addition, Lorenz curves were generated and illustrated at the drug-class level. MPR, PDC, MPR/PDC ratio, Lorenz-1, and Lorenz-50 values across the compounds were compared with Spearman nonparametric rank-correlations and tested to determine whether the correlation was significantly different from the null hypothesis of no correlation. Also, Friedman's test was performed to determine whether the rankings were consistent in pairwise analysis. The ability of each measure to discriminate between abusable and nonabusable compounds was evaluated using the c-statistic or area under the receiveroperator characteristic (ROC) curve. The area under the ROC curve ranged from 0.500 (inability to discriminate) to 1.00 (complete discrimination with no overlap in scores between the 2 groups).
All statistical tests were assessed with two-tailed tests and type 1 error rates of 5%, and all calculations were computed with SAS version 9.2 for Windows (SAS Institute, Cary, NC 
Methodology for Identifying Patient Cohort

■■ Results
The study cohort consisted of 6,291,810 adult patients with a mean age of 52.1 years of which 57.9% (n = 3,645,466) were female. The most commonly prescribed classes were strong opioids, followed by statins, then benzodiazepines (Table 3) .
The MPR, PDC, and MPR/PDC Ratio
The individual MPR and PDC measures were evaluated individually for each drug and at the class level. For the medication classes without a known abuse potential (calcium channel blockers, statins, and thyroid replacement), the mean MPR for individual drugs ranged from 0.62 to 0.84, and the trend across the MPR categories were generally consistent with the highest percentage of values falling in the < 0.5 and 0.8 up to < 1 MPR categories. For the remaining drug classes (hypnotics, benzodiazepines, strong and weak opioids, 9 short-and long-acting stimulants), the mean MPR for individual drugs was lower, ranging from 0.05 to 0. The class-level MPR/PDC ratio (MPR:PDC) ranged from 1.02-1.09. Across classes, weak opioids had the lowest MPR:PDC (1.02), while thyroid replacement and long-acting stimulants had the highest MPR:PDC (both 1.09). For individual drugs within classes, there did appear to be some outliers: morphine (1.14), oxycodone (1.13), and dextroamphetamine (1.12).
Lorenz-1 and Lorenz-50 Curves
Graphs of the Lorenz curves also show a different pattern across drug classes (5 classes illustrated in Figure 3) . High values of the Lorenz-1 percentile describes heavy users of a particular drug and were seen for the overall classes of strong opioids, benzodiazepines, and weak opioids. Highest values for the Lorenz-1 were seen for acetaminophen with codeine (29.1%), acetaminophen with oxycodone (21.5%), oxycodone (18.4%), and acetaminophen with hydrocodone (18.3%). High values of the Lorenz-50 percentile implies widespread occurrence of occasional sporadic use. Highest values of the Lorenz-50 were seen for the overall classes of strong opioids (96.1%), benzodiazepines (95.3%), and weak opioids (92.8%).
Correlation Across Measures
Assessment of the correlation of the various measures across all compounds is shown in Table 4 . The individual MPR and PDC were strongly correlated to each other, moderately correlated with the MPR:PDC, and were moderately inversely cor-
Formula
Measures
MPR
The sum of days supply divided by the number of days in the study period Mean ± standard deviation MPR ≤ 0.5 MPR = 0.5 to < 0.8 MPR = 0.8 to < 1.0 MPR > 1.0 PDC The proportion of days within the study period that the patient had an available supply of medication.
Mean ± standard deviation PDC ≤ 0.5 PDC = 0.5 to < 0.8 PDC = 0.8 to < 1.0 MPR/PDC ratio MPR divided by the PDC Mean ± standard deviation Lorenz-1 percentile
The share of the total drug volume purchased by the 1% most heavily consuming users of the drug Percentage Lorenz-50 percentile
The share of drug volume purchased by the 50% most heavily consuming users of the drug Percentage MPR = medication possession ratio; PDC = proportion of days covered. 
Number of Patients in Each Medication Cohort
related with the Lorenz-1 for all compounds, but this was only statistically significant for the abusable class when evaluated separately from the nonabusable class. The individual MPR and PDC were inversely correlated with the Lorenz-50, with a higher correlation seen for the nonabusable compounds. The MPR:PDC was also inversely correlated with the Lorenz-1, although to a higher degree in the nonabusable class. The correlation with the Lorenz-50, however, was not statistically significant for either class.
Distribution of Drugs by MPR, PDC, MPR:PDC, and Lorenz Percentiles
The individual drugs were rank ordered highest to lowest by each of the measures to explore whether the distributions were similar or different across measures and to determine the ability of each measure to discriminate between abusable and nonabusable drugs (Table 5 ). To illustrate the similarities and differences among the 5 measures, Table 6 tions. While some abusable drugs had relatively high MPR:PDCs (e.g., 1.14 for morphine and 1.13 for oxycodone), certain control medications also had high ratios (e.g., 1.09 for levothyroxine), and other agents with known abuse potential had some of the lowest ratios (e.g., 1.01 for weak opioids). We speculate that using the percentage of individuals with an MPR:PDC greater than a given threshold might be a more sensitive approach than using only the population-level mean value. Our findings suggest that measures derived from the Lorenz curve might be somewhat better suited to quantifying nonmedical use. For example, the Lorenz-1 would by definition be expected to be greatly influenced by a small group of very heavy drug users, in which individuals abusing or diverting a medication might be overrepresented. It has been suggested that a Lorenz-1 greater than 15% is considered a strong indicator that
■■ Discussion
In this analysis of a large database of patient-level prescription drug claims, we calculated and qualitatively examined an array of drug utilization measures for 1 set of medications known to be subject to abuse and diversion and another set not prone to such use. The most commonly prescribed of the former were strong opioids (48.1% of all prescriptions), while the most commonly prescribed of the latter were statins (32.4% of all prescriptions). While medications in these 2 categories demonstrated significantly different patterns across the utilization measures examined, the ability of these measures to serve as reliable indicators of the extent of nonmedical prescribing may be limited for reasons we shall discuss.
The MPR and PDC are routinely used to assess levels of patient adherence and compliance to prescribed therapy, important targets in drug utilization review, and quality improvement efforts. While mean MPR and PDC values that we observed for medications with known abuse potential were in all cases lower than for those without, this may simply reflect the fact that these agents are often used on an acute, short-term basis, while the nonabusable medications we selected are more often used chronically. Furthermore, the population mean MPR and PDC may be more subject to overall variability in therapeutic use than to heavy use by the small number of individuals using these agents nonmedically, making them less useful for quantifying nonmedical use.
The MPR:PDC, while intuitively appealing, in fact proved inferior to MPR or PDC alone in its ability to discriminate between the categories of abusable and nonabusable medica- only population-level measures (e.g., mean MPR) rather than measures based on the percentage of patients meeting various criteria (e.g., an MPR:PDC greater than 1). Third, we treated the data as a single, static cross-sectional snapshot rather than leveraging the longitudinal nature of the data source. Making use of trends in the prescription data could enable the development of algorithms optimized for the monitoring of nonmedical use patterns over time, just as knowledge of temporal trends in nonmedical use could serve as an external standard against which to validate. Fourth, as the prescribed directions for use were not available through the MarketScan database, we were not able to proactively distinguish between patients taking drugs when needed versus regularly. Fifth, we included all diagnoses, thus, not excluding patients who may have a diagnosis where overuse of medications may be appropriate/ necessary (e.g., cancer). Finally, only prescriptions reimbursed by commercial payers were captured, and it is not clear how much of the overall problem of prescription drug abuse and diversion are captured in this way, as many patients abusing medications may be paying cash.
■■ Conclusions
There is a need for valid and reliable algorithms to detect the extent of nonmedical use at a population level for surveillance purposes and to help target public health interventions aimed a drug is being abused. 7, 11 In our study, the strong opioids had the highest Lorenz-1 values, ranging from 15.5% to 30.2%, consistent with the finding of a Lorenz-1 of 19.3% for opioid analgesics observed in studies by Hallas and Nissen (1994) 7 and Hallas and Stovring (2006). 11 In contrast, Lorenz-1 values for our nonabusable control medications were generally less than 5%. It should be noted, however, that among the strong opioids, oxycodone-which is known to be widely abused and diverted and for which prescribing has increased dramatically in recent years 12 -had the next-to-lowest Lorenz-1 value (18.6%). Picking the optimal Lorenz threshold for use would require a greater understanding of the distribution of total drug supply obtained by nonmedical users, as well as the number of nonmedical users as a percentage of all users.
Limitations
By far, the greatest barrier to characterizing nonmedical use at the population level is the inability to definitively ascertain nonmedical use at the individual patient level. Our approach was limited to comparing utilization patterns between abusable and nonabusable drugs. Future studies linking claims to other data sources that permit direct assessment of nonmedical use (e.g., patient survey data) would permit development of algorithms with greater criterion validity that could then be used with greater confidence. Second, as previously stated, we explored Study concept and design were contributed by Birt, Johnston, and Nelson, with assistance from Peter Classi. Data were collected by Birt, Johnston, and Nelson, with assistance from Jin Xie. Intepretation of data was primarily the responsibility of Johnston and Nelson, with assistance from Birt. The manuscript was written by Birt and Johnston, with assistance from Nelson, and revised by Johnston and Birt, assisted by Nelson.
